Trinity Delta Lighthouse: Futura Medical
Trinity Delta view: 2023 is set to be a pivotal year for Futura Medical, with first potential launches of MED3000/Eroxon. These include in the key regions of Europe during H123, and in the US, once marketing authorisation has been granted; this continues to be expected by end-Q123. US commercialisation will be dependent on securing a partner, and it is encouraging that discussions are ongoing. First approvals in the Middle East is a positive step towards broadening Eroxon’s reach, although we continue to see the biggest potential for MED3000 in the US and in Europe, as outlined in our November 2022 Update. Successful commercialisation in either of these territories could transform Futura Medical, in our view. The market opportunity as the first clinically proven erectile dysfunction (ED) treatment available OTC (over-the-counter) and with a differentiated and rapid onset of action (ahead of typical oral PDE5 treatments) could be significant. Our Futura Medical valuation is £270m, equivalent to 94p per share, with the US opportunity alone more than underpinning the current share price.Futura Medical is engaged in the research and development of pharmaceutical drugs and medical devices and their commercial exploitation. Co. focuses on developing products primarily for the consumer healthcare market. Co.'s focus is on sexual healthcare and pain relief. DermaSys® is Co.'s transdermal technology platform, for the absorption of active molecules through the skin. DermaSys® includes MED2002, a topical gel for the treatment of erectile dysfunction; TPR100, a topical diclofenac pain relief gel; TIB200, a topical ibuprofen pain relief gel; and SPR300, a topical methyl salicylate pain relief gel.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.